The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis.

AIM To determine whether gadolinium-enhanced cardiac MRI (CMR) was of additional diagnostic value to standard assessment in patients with sarcoidosis who underwent evaluation for cardiac involvement. METHODS We reviewed the findings in patients with pulmonary sarcoidosis who had been assessed with ECG, Doppler echocardiography, 201Tl scintigraphy, and CMR from 2002 to 2004. RESULTS Of the 55 evaluated patients, standard evaluation diagnosed cardiac involvement in 13 patients while CMR diagnosed myocardial scarring (mean +/- SD, 2.5 +/- 1.9 segments) [all 6 patients] and impaired systolic left ventricular function (1 patient) in an additional 6 patients. The extent of delayed enhancement correlated with disease duration (p < 0.05), ventricular dimensions and function (p < 0.001), severity of mitral regurgitation (p < 0.05), and the presence of ventricular tachycardias (p < 0.001). Patients in whom cardiac involvement was diagnosed only with CMR had less myocardial scarring and functional impairment (p < 0.05) compared to patients with a diagnosis made by standard assessment. CONCLUSION CMR provides an accurate estimation of the extent of cardiac involvement and may reveal signs of early infiltration that are not detected by standard assessment. The extent of late enhancement with gadolinium relates to the severity of cardiac involvement and may therefore have prognostic implications.

[1]  P. Bjerle,et al.  ECG abnormalities in patients with sarcoidosis. , 2009, Acta medica Scandinavica.

[2]  Y. Aizawa,et al.  Ventricular tachyarrhythmia associated with cardiac sarcoidosis: Its mechanisms and outcome , 2004, Clinical cardiology.

[3]  D. Dusser,et al.  Apport de l'IRM dans l'exploration de l'atteinte cardiaque au cours de la sarcoïdose , 2003 .

[4]  R. Kim,et al.  Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study , 2003, The Lancet.

[5]  O. Vignaux,et al.  Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. , 2002, Chest.

[6]  R. Baughman,et al.  Cardiac involvement in sarcoidosis. , 2002, Seminars in respiratory and critical care medicine.

[7]  C. Sköld,et al.  Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography , 2002, Journal of internal medicine.

[8]  O. Vignaux,et al.  Detection of Myocardial Involvement in Patients with Sarcoidosis Applying T2-Weighted, Contrast-Enhanced, and Cine Magnetic Resonance Imaging: Initial Results of a Prospective Study , 2002, Journal of computer assisted tomography.

[9]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[10]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[11]  M. Nieminen,et al.  Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. , 2001, Journal of the American College of Cardiology.

[12]  R. Maruyama,et al.  Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. , 2001, The American journal of medicine.

[13]  J. Schulz-Menger,et al.  Visualization of cardiac involvement in patients with systemic sarcoidosis applying contrast-enhanced magnetic resonance imaging , 2000, Magma: Magnetic Resonance Materials in Physics, Biology, and Medicine.

[14]  M. Matsuki,et al.  MR findings of myocardial sarcoidosis. , 2000, Clinical radiology.

[15]  T. Michele,et al.  The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. , 1999, Medicine.

[16]  M. Isobe,et al.  Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. , 1998, The American journal of cardiology.

[17]  M. Doherty,et al.  Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment. , 1998, Respiratory medicine.

[18]  Randolph P. Martin,et al.  Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  R. Pettigrew,et al.  Diagnosis of cardiac sarcoidosis aided by MRI. , 1996, Chest.

[20]  T. Suzuki,et al.  Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. , 1994, Chest.

[21]  A. Movahed,et al.  Sarcoidosis of the Heart , 1993, Clinical cardiology.

[22]  M. Cosio,et al.  Subclinical cardiac dysfunction in sarcoidosis. , 1991, Chest.

[23]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[24]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[25]  K. Bailey,et al.  Two-dimensional echocardiographic findings in systemic sarcoidosis. , 1989, The American journal of cardiology.

[26]  James Dg.  Sarcoidosis and other granulomatous disorders , 1988 .

[27]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[28]  R. Lewin,et al.  Echocardiographic evaluation of patients with systemic sarcoidosis. , 1985, American heart journal.

[29]  L. Haywood,et al.  Detection of myocardial sarcoidosis by thallium 201 imaging. , 1982, Journal of the National Medical Association.

[30]  W. Reeves,et al.  Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. , 1980, The American journal of medicine.

[31]  G. Hutchins,et al.  Cardiac Sarcoid: A Clinicopathologic Study of 84 Unselected Patients with Systemic Sarcoidosis , 1978, Circulation.

[32]  W. Roberts,et al.  Sarcoidosis of the heart: A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II) , 1977 .

[33]  K. Iwai,et al.  CLINICOPATHOLOGICAL STUDY ON FATAL MYOCARDIAL SARCOIDOSIS * , 1976, Annals of the New York Academy of Sciences.

[34]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[35]  O. Vignaux.  Cardiac sarcoidosis: spectrum of MRI features. , 2005, AJR. American journal of roentgenology.

[36]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[37]  Y. Murakami,et al.  Clinical significance of gadolinium-DTPA-enhanced MRI for detection of myocardial lesions in a patient with sarcoidosis. , 1999, Clinical radiology.

[38]  T. Marwick,et al.  Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. , 1996, Chest.

[39]  D. Le Guludec,et al.  Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. , 1994, Chest.

[40]  C. Vamvalis,et al.  Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. , 1992, Postgraduate medical journal.